How can doctors and the medical community improve care to patients who are diagnosed with Alzheimer’s and Parkinson’s during pre-clinical and clinical stages? Even before new drugs have been approved, early detection is critical in managing – or even reversing – the course of the disease. Meet Amprion and its small group of scientists on a mission to stop Alzheimer’s and Parkinson’s before we lose another generation. Through Amprion’s revolutionary Early Detection Prion Testing, you and your doctors can now track the biomarkers or prions (aka misfolded proteins) that cause Alzheimer’s and Parkinson’s. Find out why accurate, early diagnosis of Alzheimer’s and Parkinson’s has been so challenging. Through Amprion’s breakthrough Prion Early Detection Science, we now have a 20/20 vision to track the actual footprint of all three biomarkers or prions that drive the progression of Alzheimer’s and Parkinson’s before the start of any clinical symptoms.